<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31667754</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.</ArticleTitle><Pagination><StartPage>1115</StartPage><EndPage>1132</EndPage><MedlinePgn>1115-1132</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00797-2</ELocationID><Abstract><AbstractText>In 2011, a hexanucleotide repeat expansion in the first intron of the C9orf72 gene was identified as the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The proposed disease mechanisms include loss of C9orf72 function and gain of toxicity from the bidirectionally transcribed repeat-containing RNAs. Over the last few years, substantial progress has been made to determine the contribution of loss and gain of function in disease pathogenesis. The extensive body of molecular, cellular, animal, and human neuropathological studies is conflicted, but the predominance of evidence favors gain of toxicity as the main pathogenic mechanism for C9orf72 repeat expansions. Alterations in several downstream cellular functions, such as nucleocytoplasmic transport and autophagy, are implicated. Exciting progress has also been made in therapy development targeting this mutation, such as by antisense oligonucleotide therapies targeting sense transcripts and small molecules targeting nucleocytoplasmic transport, and these are now in phase 1 clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9519-4992</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Emory University, Atlanta, GA, 30322, USA. jie.jiang@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California at San Diego, La Jolla, CA, 92093, USA. jravits@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS088578</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">RNA foci</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotide</Keyword><Keyword MajorTopicYN="N">dipeptide repeat proteins</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31667754</ArticleId><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="doi">10.1007/s13311-019-00797-2</ArticleId><ArticleId IdType="pii">10.1007/s13311-019-00797-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Spina S, Miller BL. Frontotemporal Dementia. Neurol Clin. 2017;35(2):339&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472209</ArticleId><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng AS, Rademakers R, Miller BL. Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann N Y Acad Sci. 2015;1338:71&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399703</ArticleId><ArticleId IdType="pubmed">25557955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurology. 2012;11(1):54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34(6):404&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nature Reviews Genetics. 2010;11(4):247&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4704680</ArticleId><ArticleId IdType="pubmed">20177426</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. American Journal of Human Genetics. 2013;92(3):345&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman VL, Cooper-Knock J, Connor-Robson N, Higginbottom A, Kirby J, Razinskaya OD, et al. Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation. Molecular Neurodegeneration. 2013;8:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3626718</ArticleId><ArticleId IdType="pubmed">23566336</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C, Hallupp M, Loy CT, Thompson EM, Haan E, Sue CM, et al. C9ORF72 repeat expansion in Australian and Spanish frontotemporal dementia patients. PLoS One. 2013;8(2):e56899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577667</ArticleId><ArticleId IdType="pubmed">23437264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A, Marroquin N, Schmoll B, Vielhaber S, Just M, Mayer B, et al. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiology of Aging. 2014;35(5):1214.e1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24378086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiura H, Takahashi Y, Mitsui J, Yoshida S, Kihira T, Kokubo Y, et al. C9ORF72 repeat expansion in amyotrophic lateral sclerosis in the Kii peninsula of Japan. Archives of Neurology. 2012;69(9):1154&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22637429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Molecular Psychiatry. 2016;21(8):1112&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Gutowski NJ, Edbauer D, Hilton DA, Stephens M, Rankin J, et al. Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathologica. 2014;127(3):451&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445903</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, et al. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurology. 2017;74(4):445&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28192553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Human Molecular Genetics. 2015;24(11):3133&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurology. 2013;12(10):978&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L, Rossi G, Glionna M, Tonoli E, Piccoli E, Fostinelli S, et al. C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a genotype-phenotype correlation study. Journal of Alzheimer&#x2019;s Disease: JAD. 2014;38(4):799&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">24064469</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Garcia-Redondo A, Rojas-Garcia R, Sanchez-Valle R, Noguera A, Gomez-Tortosa E, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Human Molecular Genetics. 2014;23(3):749&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, Wood EM, Toledo JB, Rennert L, et al. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica. 2015;130(3):363&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Blauwendraat C, Heetveld S, Lynes EM, Castillo-Lizardo M, Dhingra A, et al. C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathologica Communications. 2016;4(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832459</ArticleId><ArticleId IdType="pubmed">27079381</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507(7491):195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. American Journal of Human Genetics. 2013;92(6):981&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, Fratta P, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathologica. 2015;129(5):715&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">25716178</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Bauer PO, Prudencio M, Gendron TF, Stetler CT, Yan IK, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathologica. 2013;126(6):895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830740</ArticleId><ArticleId IdType="pubmed">24166615</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, Degroot S, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathologica. 2013;126(3):385&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, Li Y, Chang WH, Hung ST, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nature Medicine. 2018;24(3):313&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Gendron TF, Baker MC, DeJesus-Hernandez M, Finch NA, Brown PH, et al. Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica. 2015;130(6):863&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655160</ArticleId><ArticleId IdType="pubmed">26437865</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, Baumer D, East S, Neal J, Morris HR, Ansorge O, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging. 2014;35(7):1779 e5- e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui-Bories J, Martinat C, et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathologica Communications. 2018;6(1):72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, et al. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathologica. 2018;135(3):459&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, MacNair L, McGoldrick P, McKeever PM, McLean JR, Zhang M, et al. Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Annals of Neurology. 2015;78(4):568&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">26174152</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, Wong LH, Hayes MJ. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics (Oxford, England) 2013;29(4):499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Iyer LM, He F, Aravind L. Discovery of Novel DENN Proteins: Implications for the Evolution of Eukaryotic Intracellular Membrane Structures and Human Disease. Frontiers in Genetics. 2012;3:283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521125</ArticleId><ArticleId IdType="pubmed">23248642</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Roczniak-Ferguson A, Ferguson SM. C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. Molecular Biology of the Cell. 2016;27(20):3040&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063613</ArticleId><ArticleId IdType="pubmed">27559131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, Nayak A, Schaeffer V, Starzetz T, Kirsch AK, Muller S, et al. Multiplex image-based autophagy RNAi screening identifies SMCR8 as ULK1 kinase activity and gene expression regulator. eLife. 2017;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5323046</ArticleId><ArticleId IdType="pubmed">28195531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Campanari ML, Julie Corbier C, Gaucherot A, Kolb-Cheynel I, Oulad-Abdelghani M, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. The EMBO Journal. 2016;35(12):1276&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Zhou X, Robins AM, Paushter DH, Kim D, Smolka MB, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathologica Communications. 2016;4(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolino J, Ji YJ, Conchina K, Chu J, Nirujogi RS, Pandey A, et al. Loss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling. PLoS Genetics. 2016;12(11):e1006443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119725</ArticleId><ArticleId IdType="pubmed">27875531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Liang C, Swaminathan K, Herrlinger S, Lai F, Shiekhattar R, et al. A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Science Advances. 2016;2(9):e1601167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010369</ArticleId><ArticleId IdType="pubmed">27617292</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RA, Levina V, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Human Molecular Genetics. 2014;23(13):3579&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, Smith EF, Bauer CS, Moller A, Hautbergue GM, Ferraiuolo L, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. The EMBO Journal. 2016;35(15):1656&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki Y, Manzano R, Lee Y, Dafinca R, Aoki M, Douglas AGL, et al. C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain: a journal of neurology. 2017;140(4):887&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">28334866</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharjan N, Kunzli C, Buthey K, Saxena S. C9ORF72 Regulates Stress Granule Formation and Its Deficiency Impairs Stress Granule Assembly. Hypersensitizing Cells to Stress. Molecular Neurobiology. 2017;54(4):3062&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">27037575</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms MB, Cady J, Zaidman C, Cooper P, Bali T, Allred P, et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiology of Aging. 2013;34(9):2234 e13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679344</ArticleId><ArticleId IdType="pubmed">23597494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Liu Q, Lu CX, Cui B, Guo XN, Wang RR, et al. Identification of a novel loss-of-function C9orf72 splice site mutation in a patient with amyotrophic lateral sclerosis. Neurobiology of Aging. 2016;47:219.e1-.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27595458</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Poulter M, Lashley T, Rohrer JD, Polke JM, Beck J, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathologica. 2013;126(3):401&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Annals of Neurology. 2013;74(2):180&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh TH, Liu HF, Li YW, Lu CS, Shih HY, Chiu CC, et al. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Experimental Neurology. 2018;304:114&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">29522758</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA, Parker JA. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One. 2013;8(12):e83450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, Tai YK, Chang JC, Liang J, Tyan SH, Chen S, et al. The ALS-FTD-linked gene product, C9orf72, regulates neuronal morphogenesis via autophagy. Autophagy. 2019;15(5):827&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526867</ArticleId><ArticleId IdType="pubmed">30669939</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(47):E4530&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M, Blokhuis AM, Westeneng HJ, Terpstra ML, Zundel CA. Vieira de Sa R, et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Annals of Neurology. 2015;78(3):426&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Scientific Reports. 2016;6:23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudria-Lopez E, Koppers M, de Wit M, van der Meer C, Westeneng HJ, Zundel CA, et al. Full ablation of C9orf72 in mice causes immune system-related pathology and neoplastic events but no motor neuron defects. Acta Neuropathologica. 2016;132(1):145&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911370</ArticleId><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science (New York, NY) 2016;351(6279):1324&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Science Translational Medicine. 2016;8(347):347&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture. Neurology(R) Neuroimmunology &amp; Neuroinflammation. 2016;3(6):e301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5087253</ArticleId><ArticleId IdType="pubmed">27844039</ArticleId></ArticleIdList></Reference><Reference><Citation>Molteni M, Rossetti C. Neurodegenerative diseases: The immunological perspective. J Neuroimmunol. 2017;313:109&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29153601</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Wu K, Neal D, Suh E, McNally AG, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathologica. 2014;128(4):525&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161616</ArticleId><ArticleId IdType="pubmed">24806409</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Russ J, Wood EM, Irwin DJ, Grossman M, McCluskey L, et al. C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and Neuropathologic Evidence. Neurology. 2015;84(16):1622&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409587</ArticleId><ArticleId IdType="pubmed">25795648</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ J, Liu EY, Wu K, Neal D, Suh E, Irwin DJ, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathologica. 2015;129(1):39&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282973</ArticleId><ArticleId IdType="pubmed">25388784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Mizielinska S, Nicoll AJ, Zloh M, Fisher EM, Parkinson G, et al. C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Scientific Reports. 2012;2:1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527825</ArticleId><ArticleId IdType="pubmed">23264878</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SY, Macgregor RB, Jr, Pearson CE. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures. The Journal of Biological Chemistry. 2013;288(14):9860&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda A, Zalar M, Sket P, Plavec J, Rogelj B. Anti-sense DNA d(GGCCCC)n expansions in C9ORF72 form i-motifs and protonated hairpins. Scientific Reports. 2015;5:17944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668579</ArticleId><ArticleId IdType="pubmed">26632347</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimov F, Kunkel LM. The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. The Journal of Cell Biology. 2013;201(4):499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653356</ArticleId><ArticleId IdType="pubmed">23671309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG, Wharton SB, et al. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathologica. 2015;130(1):63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468790</ArticleId><ArticleId IdType="pubmed">25943887</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathologica. 2013;126(6):829&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathologica. 2013;126(6):845&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(51):E4968&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathologica. 2013;126(6):881&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science (New York, NY). 2013;339(6125):1335&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77(4):639&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR, et al. Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathologica. 2015;130(6):845&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E, Kupper C, et al. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathologica. 2015;130(4):537&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Deza J, Lee YB, Troakes C, Nolan M, Al-Sarraj S, Gallo JM, et al. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathologica Communications. 2015;3:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479315</ArticleId><ArticleId IdType="pubmed">26108573</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper LJ, Raaphorst J, Aronica E, Baas F, de Haan R, de Visser M, et al. Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: a systematic neuropathological review. Neuropathology and Applied Neurobiology. 2016;42(6):547&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26373655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Oeckl P, Weishaupt JH, Volk AE, Diehl-Schmid J, Schroeter ML, et al. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol Med. 2017;9(7):859&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Science Translational Medicine. 2017;9(383).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83(5):1043&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84(6):1213&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Hao L, Saur T, Joyal K, Zhao Y, Zhai D, et al. Forward Genetic Screen in Caenorhabditis elegans Suggests F57A10.2 and acp-4 As Suppressors of C9ORF72 Related Phenotypes. Front Mol Neurosci. 2016;9:113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100550</ArticleId><ArticleId IdType="pubmed">27877110</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Bento-Abreu A, Gendron TF, Boeynaems S, Bogaert E, Nuyts R, et al. A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. Acta Neuropathologica. 2018;135(3):427&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29302778</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Poidevin M, Li X, Li Y, Shu L, Nelson DL, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(19):7778&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science (New York, NY) 2014;345(6201):1192&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, Sasaguri H, Zhang YJ, Castanedes-Casey M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science (New York, NY) 2015;348(6239):1151&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM, et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Molecular Neurodegeneration. 2019;14(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Muhammad A, Gendron TF, Kim KJ, Austin A, et al. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015;88(5):892&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, et al. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015;88(5):902&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90(3):535&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, et al. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90(3):521&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Aladesuyi Arogundade O, Stauffer JE, Saberi S, Diaz-Garcia S, Malik S, Basilim H, et al. Antisense RNA foci are associated with nucleoli and TDP-43 mislocalization in C9orf72-ALS/FTD: a quantitative study. Acta Neuropathologica. 2019;137(3):527&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397670</ArticleId><ArticleId IdType="pubmed">30666413</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, et al. In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica. 2017;134(2):255&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, Mizielinska S, Niccoli T, Mitchell JS, Thoeng A, Ridler CE, et al. Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. Acta Neuropathologica. 2018;135(3):445&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385858</ArticleId><ArticleId IdType="pubmed">29380049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Almeida S, Moore J, Gendron TF, Chalasani U, Lu Y, et al. Differential Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of C9ORF72 FTD/ALS. Neuron. 2015;87(6):1207&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, O&#x2019;Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Science Translational Medicine. 2013;5(208):208&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Reports. 2013;5(5):1178&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Lammich S, Mackenzie IR, Forne I, Zilow S, Kretzschmar H, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathologica. 2013;125(3):413&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. eLife. 2016;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Celona B, Dollen JV, Vatsavayai SC, Kashima R, Johnson JR, Tang AA, et al. Suppression of C9orf72 RNA repeat-induced neurotoxicity by the ALS-associated RNA-binding protein Zfp106. eLife. 2017;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5283830</ArticleId><ArticleId IdType="pubmed">28072389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Walsh MJ, Higginbottom A, Robin Highley J, Dickman MJ, Edbauer D, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain: a journal of neurology. 2014;137(Pt 7):2040&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS, Barker H, Robinson AC, Thompson JC, Harris J, Troakes C, et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathologica Communications. 2014;2:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229740</ArticleId><ArticleId IdType="pubmed">24950788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathologica. 2013;126(6):859&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N, Bieniek KF, Zhang YJ, Ross K, Gendron TF, Murray ME, et al. Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathologica Communications. 2018;6(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nature Neuroscience. 2015;18(9):1226&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z, Wang H, Xia Q, Li K, Li K, Jiang X, et al. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Human Molecular Genetics. 2015;24(9):2426&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, et al. C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell. 2016;167(3):774&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(1):260&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, et al. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Human Molecular Genetics. 2016;25(9):1803&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986334</ArticleId><ArticleId IdType="pubmed">26931465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL, et al. Aggregation-pronec9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathologica. 2014;128(4):505&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, et al. C9orf72 FTLD/ALS-associatedGly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathologica. 2014;128(4):485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamakawa M, Ito D, Honda T, Kubo K, Noda M, Nakajima K, et al. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Human Molecular Genetics. 2015;24(6):1630&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">25398948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Abdallah A, Li Z, Lu Y, Almeida S, Gao FB. FTD/ALS-associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathologica. 2015;130(4):525&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575383</ArticleId><ArticleId IdType="pubmed">26031661</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovicic A, et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Scientific Reports. 2016;6:20877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan A, Bouffard M, Liao M, Ryan S, Callister JB, Pickering-Brown SM, et al. Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model. Human Molecular Genetics. 2018;27(10):1754&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932562</ArticleId><ArticleId IdType="pubmed">29528390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohki Y, Wenninger-Weinzierl A, Hruscha A, Asakawa K, Kawakami K, Haass C, et al. Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. Molecular Neurodegeneration. 2017;12(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237533</ArticleId><ArticleId IdType="pubmed">28088213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nature Neuroscience. 2016;19(5):668&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, et al. Spinal poly-GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathologica. 2017;134(2):241&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508040</ArticleId><ArticleId IdType="pubmed">28409281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Ebbert MTW, O&#x2019;Raw AD, Yue M, Jansen-West K, et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nature Medicine. 2018;24(8):1136&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520050</ArticleId><ArticleId IdType="pubmed">29942091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science (New York, NY). 2019;363(6428).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SY, Lopez-Gonzalez R, Krishnan G, Phillips HL, Li AN, Seeley WW, et al. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nature Neuroscience. 2019;22(6):851&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z, Liu L, Tao Z, Wang R, Ren H, Sun H, et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nature Communications. 2019;10(1):2906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606620</ArticleId><ArticleId IdType="pubmed">31266945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science (New York, NY) 2014;345(6201):1139&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores BN, Dulchavsky ME, Krans A, Sawaya MR, Paulson HL, Todd PK, et al. Distinct C9orf72-Associated Dipeptide Repeat Structures Correlate with Neuronal Toxicity. PLoS One. 2016;11(10):e0165084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5077081</ArticleId><ArticleId IdType="pubmed">27776165</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Q, Liang C, Chang Q, Zhang W, Yang M, Chen JF. C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner. Acta Neuropathologica Communications. 2019;7(1):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398253</ArticleId><ArticleId IdType="pubmed">30832726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Lehmer C, Michaelsen M, Mori K, Alterauge D, Baumjohann D, et al. Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins. EMBO Mol Med. 2017;9(5):687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabet R, Schaeffer L, Freyermuth F, Jambeau M, Workman M, Lee CZ, et al. CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts. Nature Communications. 2018;9(1):152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764992</ArticleId><ArticleId IdType="pubmed">29323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojciechowska M, Olejniczak M, Galka-Marciniak P, Jazurek M, Krzyzosiak WJ. RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders. Nucleic Acids Research. 2014;42(19):11849&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4231732</ArticleId><ArticleId IdType="pubmed">25217582</ArticleId></ArticleIdList></Reference><Reference><Citation>Knockenhauer KE, Schwartz TU. The Nuclear Pore Complex as a Flexible and Dynamic Gate. Cell. 2016;164(6):1162&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4788809</ArticleId><ArticleId IdType="pubmed">26967283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ, Haney MS, Morgens DW, Jovicic A, Couthouis J, Li A, et al. CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nature Genetics. 2018;50(4):603&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(7):E1111&#x2013;E7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320981</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, et al. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer&#x2019;s Disease. Neuron. 2019;101(2):349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377243</ArticleId><ArticleId IdType="pubmed">30653936</ArticleId></ArticleIdList></Reference><Reference><Citation>Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, et al. Mutant Huntingtin Disrupts the Nuclear Pore Complex. Neuron. 2017;94(1):93&#x2013;107.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5595097</ArticleId><ArticleId IdType="pubmed">28384479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, et al. Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. Neuron. 2017;94(1):48&#x2013;57.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Ridler CE, Balendra R, Thoeng A, Woodling NS, Grasser FA, et al. Bidirectional nucleolar dysfunction in C9orf72 frontotemporal lobar degeneration. Acta Neuropathologica Communications. 2017;5(1):29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395972</ArticleId><ArticleId IdType="pubmed">28420437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, Lu Y, Gendron TF, Karydas A, Tran H, Yang D, et al. Poly(GR) in C9ORF72-RelatedALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92(2):383&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Konopka A, Soo KY, Ito D, Atkin JD. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Human Molecular Genetics. 2017;26(15):2882&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, Yang D, Pribadi M, Kim TS, Krishnan G, Choi SY, et al. Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9ORF72-ALS/FTD. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(19):9628&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511021</ArticleId><ArticleId IdType="pubmed">31019093</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. The Journal of Cell Biology. 2013;201(3):361&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163(1):123&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Qamar S, Lin JQ, Schierle GS, Rees E, Miyashita A, et al. ALS/FTDMutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron. 2015;88(4):678&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162(5):1066&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149(4):753&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Kovacs D, Konijnenberg A, Timmerman E, Volkov A, et al. Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. Molecular Cell. 2017;65(6):1044&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, et al. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173(4):958&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Vale RD. RNA phase transitions in repeat expansion disorders. Nature. 2017;546(7657):243&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5555642</ArticleId><ArticleId IdType="pubmed">28562589</ArticleId></ArticleIdList></Reference><Reference><Citation>Fay MM, Anderson PJ, Ivanov P. ALS/FTD-Associated C9ORF72 Repeat RNA Promotes Phase Transitions In Vitro and in Cells. Cell Reports. 2017;21(12):3573&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741101</ArticleId><ArticleId IdType="pubmed">29262335</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, et al. RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nature Communications. 2017;8(1):2005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lehmer C, Martinez-Sanchez A, Rudack T, Beck F, Hartmann H, et al. In Situ Structure of Neuronal C9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment. Cell. 2018;172(4):696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CF, Krainer AR, Cleveland DW. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annual Review of Neuroscience. 2019;42:385&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427431</ArticleId><ArticleId IdType="pubmed">31283897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biology. 2007;5(4):e73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820610</ArticleId><ArticleId IdType="pubmed">17355180</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurology. 2013;12(5):435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting Huntingtin Expression in Patients with Huntington&#x2019;s Disease. The New England Journal of Medicine. 2019;380(24):2307&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702667</ArticleId><ArticleId IdType="pubmed">19158789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery. 2019;18(5):358&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927556</ArticleId><ArticleId IdType="pubmed">30710128</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Rigo F, Prakash TP, Corey DR. Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. Nucleic Acid Ther. 2017;27(2):87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5372765</ArticleId><ArticleId IdType="pubmed">28005462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Liu J, Li L, Gagnon KT, Corey DR. Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. Chem Biol. 2015;22(11):1505&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4659491</ArticleId><ArticleId IdType="pubmed">26584779</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol Ther Nucleic Acids. 2019;16:26&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, et al. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol Ther Nucleic Acids. 2019;14:593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B, Reddy K, Macgregor RB, Jr, Pearson CE. TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. The Journal of Biological Chemistry. 2014;289(8):4653&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZF, Ursu A, Childs-Disney JL, Guertler R, Yang WY, Bernat V, et al. The Hairpin Form of r(G4C2)(exp) in c9ALS/FTD Is Repeat-Associated Non-ATG Translated and a Target for Bioactive Small Molecules. Cell Chemical Biology. 2019;26(2):179&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386614</ArticleId><ArticleId IdType="pubmed">30503283</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Oss SB, Cucinotta CE, Arndt KM. Emerging Insights into the Roles of the Paf1 Complex in Gene Regulation. Trends Biochem Sci. 2017;42(10):788&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658044</ArticleId><ArticleId IdType="pubmed">28870425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ, Carlomagno Y, Zhang YJ, Almeida S, Cook CN, Gendron TF, et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science (New York, NY) 2016;353(6300):708&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823025</ArticleId><ArticleId IdType="pubmed">27516603</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman LD, Prudencio M, Kramer NJ, Martinez-Ramirez LF, Srinivasan AR, Lan M, et al. Toxic expanded GGGGCC repeat transcription is mediated by the PAF1 complex in C9orf72-associated FTD. Nature Neuroscience. 2019;22(6):863&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6535128</ArticleId><ArticleId IdType="pubmed">31110321</ArticleId></ArticleIdList></Reference><Reference><Citation>Naguib A, Sandmann T, Yi F, Watts RJ, Lewcock JW, Dowdle WE. SUPT4H1 Depletion Leads to a Global Reduction in RNA. Cell Reports. 2019;26(1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30605685</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich M, Zhang F. Applications of CRISPR-Cas systems in neuroscience. Nature Reviews Neuroscience. 2016;17(1):36&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4899966</ArticleId><ArticleId IdType="pubmed">26656253</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto BS, Saxena T, Oliveira R, Mendez-Gomez HR, Cleary JD, Denes LT, et al. Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9. Molecular Cell. 2017;68(3):479&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013302</ArticleId><ArticleId IdType="pubmed">29056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, et al. Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. Cell. 2017;170(5):899&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873302</ArticleId><ArticleId IdType="pubmed">28803727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Mestre AA, Fu C, Makarem A, Xian F, et al. C9ORF72 GGGGCC repeat-associated non-AUG translation is upregulated by stress through eIF2alpha phosphorylation. Nature Communications. 2018;9(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada SB, Gendron TF, Niccoli T, Genuth NR, Grosely R, Shi Y, et al. RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats. Nature Neuroscience. 2019;22(9):1383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713615</ArticleId><ArticleId IdType="pubmed">31358992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofani R, Crippa V, Vezzoli G, Rusmini P, Galbiati M, Cicardi ME, et al. The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases. Cell Stress &amp; Chaperones. 2018;23(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741577</ArticleId><ArticleId IdType="pubmed">28608264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G, Holtzman DM. Antibody Therapeutics Targeting Abeta and Tau. Cold Spring Harbor Perspectives in Medicine. 2017;7(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500436</ArticleId><ArticleId IdType="pubmed">28062555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock EM, Polymenidou M. Prion-like propagation as a pathogenic principle in frontotemporal dementia. Journal of Neurochemistry. 2016;138(Suppl 1):163&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680357</ArticleId><ArticleId IdType="pubmed">27502124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J. Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Experimental Neurology. 2014;262(Pt B):121&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25108067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Jeng US, Chiang YL, Hwang IS, Chen YR. The Glycine-Alanine Dipeptide Repeat from C9orf72 Hexanucleotide Expansions Forms Toxic Amyloids Possessing Cell-to-Cell Transmission Properties. The Journal of Biological Chemistry. 2016;291(10):4903&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777828</ArticleId><ArticleId IdType="pubmed">26769963</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue GM, Castelli LM, Ferraiuolo L, Sanchez-Martinez A, Cooper-Knock J, Higginbottom A, et al. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nature Communications. 2017;8:16063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="pubmed">28677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EM, Li X, et al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Scientific Reports. 2018;8(1):4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Gendron TF. Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72. Frontiers in Neurology. 2018;9:1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289985</ArticleId><ArticleId IdType="pubmed">30568632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>